Table I.
Patients who have sarcoidosis associated with immune checkpoint inhibitor therapy for malignancy
| Patient demographics | Cancer diagnosis (location of metastases) | Location of sarcoidosis | Drug | Time into treatment, dose | Response to treatment | Study |
|---|---|---|---|---|---|---|
| 67 y, F | Melanoma (liver) | Lung | Ipilimumab | 5 courses, q3w, 10 mg/kg | Stable disease | Eckert et al, 20093 |
| 49 y, M | Melanoma (cutaneous, LN) | Lung (hilar and mediastinal LAD) | Ipilimumab | 6 courses q3w, 3 mg/kg | Complete remission | Vogel et al, 20124 |
| — | Prostate | Lung (aveolar) | Ipilimumab | GVAX + ipi, 5 mg/kg q4w | — | van den Eertwegh et al, 20125 |
| 52 y, F | Melanoma (lung, LN) | Lung | Ipilimumab | 2 courses, q3w, 3 mg/kg | Progression of disease | Wilgenhof et al, 20126 |
| 63 y, M | Melanoma (lung, liver, LN) | Lung | Ipilimumab | 4 cycles, q3w, 3 mg/kg | Regression of mets | Berthod et al, 20127 |
| — | Melanoma | — | Anti–PD-L1 Ab | 10 mg/kg, q2w | — | Brahmer et al, 20128 |
| 57 y, M | Melanoma (LN) | Lung, skin | Ipilimumab | 10 mg/kg, q3w x 4, then q12w x 2 | — | Tissot et al, 20139 |
| 55 y, M | Melanoma (LN) | Lung, skin | Ipilimumab | 2 courses 10 mg/kg | Developed cutaneous mets | Reule and North, 20132 |
| 37 y, M | Melanoma (LN, bone) | Lung, CNS (sella turcica) | Ipilimumab | 4 courses, q3w, 3 mg/kg | Sustained partial response | Murphy, 201410 |
| M | Melanoma | Spleen | Ipilimumab | — | Sustained partial response | Andersen et al, 201411 |
| 74 y, M | Melanoma (liver) | Granulomatous interstitial nephritis | Ipilimumab | 3 courses, 3 mg/kg | Toumeh et al, 201512 | |
| 60 y, F | Lung adenocarcinoma (LN, brain) | Skin | Ipilimumab + nivolimab | 10 cycles, 1 mg/kg | Progression of disease | Current case |
CNS, Central nervous system; LAD, lymphadenopathy; LN, lymph node; mets, metastases.